drugset
drugset / Trial / NCT04826562

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

NCT04826562 ↗

Phase 4 Unknown 40 enrolled Saint Michael's Medical Center ViiV Healthcare · collab
NaSingle-groupOpen-labelTreatment

Summary

An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 \< 50 copies/mL

Timeline

Start
2021-09-26
Primary completion
2023-10-06
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir/Lamivudine Unknown — —

Indications

HIV infectious disease